Allergen immunotherapy: 100 years, but it does not look like

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Allergen immunotherapy (AIT) represents the sole therapeutic approach targeting the root causes of allergic diseases, rather than just symptom management.
• Established a century ago, AIT's efficacy was empirically recognized for decades before the advent of controlled trials in 1954 initiated an era of scientific validation.
• Key milestones include the introduction of venom immunotherapy in 1978 for preventing anaphylaxis from insect stings.

Observation:

• Currently, AIT is administered via two primary methods for inhalant allergens: subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT).
• Extensive clinical trials and meta-analyses provide robust evidence supporting the efficacy and safety of both SCIT and SLIT in managing allergic rhinitis and asthma.
• While SCIT can present drawbacks related to adverse systemic reactions, SLIT demonstrates excellent safety and tolerability profiles when administered according to recommended guidelines.

Findings:

• The development of standardized quality tablets in Europe marked a significant advancement for SLIT.
• Ongoing research is exploring novel applications for AIT, including food allergies and atopic dermatitis, alongside new administration routes.
• AIT has maintained a central role in allergy management for 100 years, with continuous improvements suggesting a promising future.

Implications:

• AIT's evolution underscores its critical role in modern allergy treatment paradigms.
• The safety and efficacy data support AIT as a cornerstone therapy for allergic conditions.
• Future research directions indicate expanding therapeutic potential and improved patient outcomes through AIT.